Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Glatiramer acetate - Teva Pharmaceuticals

X
Drug Profile

Glatiramer acetate - Teva Pharmaceuticals

Alternative Names: COP-1; Copaxone; Copolymer-1

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Weizmann Institute of Science
  • Developer Lundbeck A/S; Proneuron Biotechnologies; Takeda; Teva Neuroscience; Teva Pharmaceutical Industries
  • Class Antiglaucomas; Neuroprotectants; Peptides; Polymers
  • Mechanism of Action Immunomodulators; MHC class II gene modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple sclerosis
  • Discontinued Amyotrophic lateral sclerosis; Glaucoma; Huntington's disease; Neurological disorders

Most Recent Events

  • 15 Sep 2020 Technical Board of Appeal (TBA) of the European Patent Office revoked European patent no. 2 949 335 related to Glatiramer acetate filed against Mylan by Teva for marketing in Europe
  • 15 Oct 2018 The United States Court of Appeals for the Federal Circuit affirms the District of Delaware's decision that Teva's Copaxone® 40 mg/mL dosing patents are invalid
  • 27 Apr 2018 Updated efficacy and safety data from the phase III GALA trial in Multiple sclerosis presented at the 70th Annual Meeting of the American Academy of Neurology (AAN-2018)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top